title: [The value of fractionated exhaled nitric oxide in the diagnosis of asthma-chronic obstructive pulmonary disease overlap syndrome].
abstract: Objective:To explore the diagnostic value of fractionated exhaled nitric oxide (FeNO) measurement in patients with asthma-chronic obstructive pulmonary disease(COPD) overlap syndrome (ACOS).Methods:Eighty-one patients with ACOS, 76 patients with asthma, 82 patients with COPD and 39 healthy non-smoking subjects were recruited in the study. Naku Lun breath analyzer was used to measure the level of FeNO in the 4 groups. Pulmonary function was also measured. The ROC curve was used to differentiate ACOS from patients with COPD. The correlation between FeNO and lung function was analyzed with Pearson correlation analysis.Results:The levels of FeNO in asthmatic group, COPD group, ACOS group and healthy group were (102.3±8.2)×10(9,) (23.7±0.6)×10(9,) (50.2±3.2)×10(9,) and (18.5±7.1)×10(9) respectively. Among the former 3 groups, the differences of FeNO were statistically significant (P<0.05). FeNO>29×10(9) was the best cutoff point to differentiate ACOS from COPD; the sensitivity was 80%, specificity was 73%, positive predictive value was 75%, and negative predictive value and accuracy was 79% and 77%. There was no correlation between FeNO and FEV(1)% or FEV(1)/FVC in ACOS, COPD and asthma groups (r=0.12, 0.11,P>0.05;r=0.11, 0.03,P>0.05;r=0.06, 0.08,P>0.05).Conclusion:FeNO is a good marker to help clinicians differentiate ACOS from COPD. FeNO>29×10(9) was the best cutoff point for the identification of patients with ACOS from COPD.
authors.affiliation: Departentment of Respiration of the Second Xiangya Hospital of Central South University, Changsha 410000, China.
authors.forename: D D
authors.initials: DD
authors.lastname: Deng
authors.forename: A Y
authors.initials: AY
authors.lastname: Zhou
authors.forename: Q C
authors.initials: QC
authors.lastname: Shuang
authors.forename: P
authors.initials: P
authors.lastname: Chen
mesh_terms: D000328:Adult; D001249:Asthma / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers / Q000378:metabolism; D001944:Breath Tests / Q000379:methods; D001985:Bronchial Provocation Tests; D016022:Case-Control Studies; D045853:Exhalation; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism*; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology; D012372:ROC Curve; D012129:Respiratory Function Tests / Q000379:methods*; D012680:Sensitivity and Specificity; D013577:Syndrome
chemical_list: D015415:Biomarkers; D009569:Nitric Oxide
keywords: Asthma; Asthma-COPD overlap syndrome; Nitric oxide; Pulmonary disease, chronic obstructive